12月29日 - ** 药物开发商Praxis Precision Medicines PRAX.O股价盘前上涨11.5%至299.9美元
** PRAX表示，美国食品和药物管理局已授予其实验性药物ulixacaltamide "突破性 "标签，用于治疗本质性震颤患者。
** 突破性疗法 "标签旨在加快开发和审查治疗严重疾病或医疗需求未得到满足的药物
** 本质性震颤是一种神经系统运动障碍，会导致手、手臂、头部或声音不自主、有节奏地颤抖。
** 截至上一交易日收盘，该公司股价已上涨两倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.